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Background
Aspirin is an effective anti-platelet agent with proven
benefit in preventing atherothrombotic complications.
However, resistance to aspirin is significantly associated
with increased risk of death, cerebrovascular accident or
myocardial infarction compared with aspirin sensitive
patients (24% vs 10%, P=0.03) and is well documented
in Western literature. It has hitherto not been estab-
lished in Sri Lanka. Our aim was to estimate the preva-
lence of aspirin resistance in patients on low dose
aspirin for primary or secondary prophylaxis and to
ascertain if patients resistant to aspirin have detectable
serum salicylic acid levels (SA).
Methods
Platelet aggregometry was performed with Adenosine
diphosphate (ADP) and Arachidonic acid in 48 patients on
aspirin 150mg daily and 12 normal controls. Serum Sal-
icylic acid levels were also estimated using High Perfor-
mance Liquid Chromatography (HPLC) on the same blood
sample. Aspirin resistance was defined as a mean platelet
aggregation of ≥70% with ADP and ≥20% with Arachidonic
acid. Aspirin semi responders were defined as those having
the above platelet aggregation levels in only one of the two
reagents used. Aspirin responders do not show acceptable
platelet aggregation with either of the reagents.
Results
Mean age of patients was 61 years (SD=9.26) with 64%
females. 24.4% were aspirin resistant, 64.5% were semi
responders and 11.1% were aspirin responders. All semi
responders showed normal aggregation with Arachidonic
Acid. Salicylic acid levels were successfully performed in
only 32 patients. Salicylic acid levels of >0.01µg/L were
detectable in 62.5% of aspirin resistant patients and
70.8% in responders.
Conclusions
Aspirin resistance among the test cohort is 24.4%.
These patients are at greater risk of developing recur-
rent vascular events in spite of being on aspirin and
may benefit by a dose increment. We suggest further
studies with larger numbers of patients.
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